Clinical Trials for SciClone Pharmaceuticals

Explore 6 clinical trials worldwide

Showing 1-6 of 6 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: SciClone Pharmaceuticals

Clinical Trials (6)

A Real-World Study of Elacestrant in Patients With HR+/HER2- Advanced Breast Cancer and ESR1 Mutations

100 participants

Started: Aug 1, 2025 · Completed: Jul 1, 2027

4 conditions1 sponsor1 location

Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer

450 participants

Started: Aug 8, 2024 · Completed: Dec 31, 2027

2 conditions1 sponsor1 location

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

350 participants

Started: Jul 13, 2024 · Completed: Aug 1, 2026

3 conditions1 sponsor1 location

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response.

PHASE4Not yet recruiting

62 participants

Started: Oct 31, 2023 · Completed: Aug 15, 2027

1 condition1 sponsor0 locations

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

PHASE2Recruiting

60 participants

Started: Apr 1, 2023 · Completed: Dec 31, 2025

2 conditions2 sponsors1 location

A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

PHASE3Active, not recruiting

292 participants

Started: Aug 1, 2022 · Completed: Dec 31, 2025

1 condition2 sponsors2 locations